| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2870959 | The Annals of Thoracic Surgery | 2016 | 6 Pages |
Abstract
Nafamostat mesilate was found to increase the bleeding risk in patients receiving venoarterial ECMO. Regarding thromboembolic complications, there was no significant difference between heparin and nafamostat. Only old age increased the thromboembolic risk.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ju Yong MD, Joon Bum MD, Suk Jung MD, Cheol Hyun MD, Jae Won MD, Sung Ho MD,